New Consensus
12/19/2024
3:43 pm
Case 1:
A 32-year-old Caucasian woman, referred to as Patient X, visits her primary care physician, reporting increased urination over the past month. During the assessment, she mentions an upcoming optometrist appointment due to recently developed blurred vision. She is 5 feet 5 inches tall and weighs 142 pounds, giving her a BMI of 23.6 kg/m². Patient X has a family history of diabetes on her father’s side and leads a predominantly sedentary lifestyle. A random finger stick test shows her blood glucose level at 257 mg/dL.
CLICK HERE FOR DIAGNOSIS
Rationale and Comments: The findings support a diabetes diagnosis, as a random blood glucose above 200 mg/dL, combined with symptoms like polyuria and blurred vision, meets the diagnostic criteria.
Patient X undergoes fasting blood tests, which yield the following results:
– HbA1c: 8.5% (estimated average glucose: 197 mg/dL)
– Fasting blood glucose:147 mg/dL
– Two-hour glucose level (after 75 g oral glucose tolerance test): 240 mg/dL
– Triglycerides: 152 mg/dL
– Low-density lipoprotein (LDL): 97 mg/dL
– HDL: 35 mg/dL
– Liver function tests: Normal
– Renal function: Normal
She is referred to an ADA-recognized diabetes education program for guidance on self-management, monitoring blood glucose, and planning meals and exercise.
After three months, Patient X returns for follow-up. Her HbA1c shows minimal improvement at 8.2% (estimated average glucose: 189 mg/dL), with a fasting blood glucose of 156 mg/dL. Self-monitoring records indicate fasting glucose levels between 135 mg/dL and 160 mg/dL, and post-meal levels ranging from 230 mg/dL to 300 mg/dL. Despite following her meal and exercise plan, she reports limited success.
CLICK HERE FOR TREATMENT
The physician reviews her blood work and medical history, concluding that initiating sulfonylurea therapy is appropriate. Patient X starts glipizide at 5 mg each morning, with a strong emphasis on continuing her meal and exercise regimen.
Rationale and Comments: This treatment plan is suitable for Patient X, given that she is not classified as obese and has adhered to her dietary and exercise guidelines with inadequate results. Elevated fasting glucose levels, combined with high postprandial readings, are contributing to her HbA1c levels. The sulfonylurea glipizide should help address the elevated post-meal glucose due to diminished first-phase insulin response.
Case 2:
Patient V is a 61-year-old Hispanic man who visits his primary care physician, reporting increased thirst, hunger, and fatigue over the past month. He mentions needing a new eyeglass prescription due to blurred vision. Standing 5 feet 10 inches tall and weighing 245 pounds, his BMI is calculated at 35.2 kg/m². With a family history of diabetes on both sides, he works in a physically demanding job lifting heavy items. A random finger stick indicates a blood glucose level of 220 mg/dL, supporting a diabetes diagnosis.
CLICK HERE FOR DIAGNOSIS
Fasting blood work results include:
– HbA1c: 8.7% (estimated average glucose: 203 mg/dL)
– Fasting blood glucose: 151 mg/dL
– Two-hour glucose level (after 75 g oral glucose tolerance test): 233 mg/dL
– Triglycerides: 210 mg/dL
– Low-density lipoprotein (LDL):112 mg/dL
– HDL: 35 mg/dL
– Liver function tests: Normal
– Renal function: Normal
Patient V is referred to an ADA-recognized diabetes education program and is scheduled for a follow-up in three months.
At the follow-up visit, his HbA1c shows slight improvement at 8.2% (estimated average glucose: 189 mg/dL) with a fasting blood glucose of 156 mg/dL. Self-monitoring records show fasting levels between 135 mg/dL and 160 mg/dL and postprandial levels between 220 mg/dL and 248 mg/dL. His lipid levels remain elevated, and he reports limited success following his dietary and exercise recommendations.
CLICK HERE FOR TREATMENT
After reviewing his progress, the physician decides to start treatment with acarbose, an alpha-glucosidase inhibitor. Patient V is prescribed 25 mg of acarbose with each meal, emphasizing the importance of adhering to culturally appropriate meal and exercise plans.
Rationale and Comments: Acarbose is a suitable choice for Patient V given his elevated lipid levels and postprandial hyperglycemia. Although fasting glucose levels are concerning, the physician identifies postprandial spikes as the primary contributor to his elevated HbA1c. This medication should help manage both his post-meal glucose and lipid levels effectively.
Case 3:
Patient K is a 71-year-old Caucasian woman who presents to her primary care physician with fatigue, increased urination, excessive thirst, and hunger over the past few months. She is 5 feet 4 inches tall, weighs 205 pounds, and has a BMI of 35.3 kg/m². Patient K has a family history of diabetes on her mother’s side, has previously given birth to a large child, and has bilateral knee arthritis. A finger stick test shows a blood glucose level of 198 mg/dL.
CLICK HERE FOR DIAGNOSIS
Rationale and Comments: Although she exhibits symptoms of diabetes, the blood glucose level of 198 mg/dL is not definitive for diagnosis without further testing.
To gather more information, Patient K undergoes a comprehensive blood work-up, revealing:
– HbA1c: 8.0% (estimated average glucose: 183 mg/dL)
– Fasting blood glucose: 195 mg/dL
– Two-hour glucose level (after 75 g oral glucose tolerance test): 160 mg/dL
– Triglycerides: 167 mg/dL
– Low-density lipoprotein (LDL): 123 mg/dL
– HDL: 29 mg/dL
– Liver function tests: Normal
– Renal function: Normal
With this information, Patient K is diagnosed with type 2 diabetes and referred to an ADA-recognized diabetes education program. During her three-month follow-up, her HbA1c increases to 8.6% (estimated average glucose: 200 mg/dL), and her fasting blood glucose is 205 mg/dL. Self-monitoring records indicate fasting levels between 180 mg/dL and 210 mg/dL and postprandial levels between 150 mg/dL and 170 mg/dL. Patient K admits she did not attend the education class but has tried to limit her sugar intake. She has avoided starting an exercise program due to knee pain.
CLICK HERE FOR TREATMENT
Considering her elevated blood glucose levels and lack of lifestyle changes, the physician prescribes metformin at 500 mg each evening, alongside recommending water aerobics. The importance of self-monitoring blood glucose and diabetes education is reiterated.
Rationale and Comments: This treatment is appropriate due to her elevated fasting and postprandial glucose levels and suspected insulin resistance. Metformin is expected to help reduce her blood glucose by decreasing liver glucose production and improving insulin sensitivity.
Follow-Up Case 3:
One year later, Patient K is on metformin, now taking 1,000 mg twice daily. At her recent appointment, her HbA1c is 8.8% (estimated average glucose: 206 mg/dL). She reports adherence to her meal and exercise plans, but sporadic self-monitoring shows fasting levels between 145 mg/dL and 170 mg/dL and postprandial levels between 180 mg/dL and 230 mg/dL. Despite slight improvements, her results are still unsatisfactory, necessitating a more intensive therapy with an additional antihyperglycemic agent. The physician prescribes glyburide at 2.5 mg daily, but Patient K expresses concern over costs due to her fixed income. The physician offers a combination medication that is more affordable, and Patient K agrees to start Glucovance 2.5 mg/500 mg in the morning while continuing metformin in the evening.
During her next follow-up three months later, her HbA1c decreases to 8.1% (estimated average glucose: 186 mg/dL) with a fasting blood glucose of 110 mg/dL. Her self-monitoring shows fasting levels between 98 mg/dL and 120 mg/dL and postprandial levels between 160 mg/dL and 200 mg/dL. Patient K has made significant progress in adhering to her meal and exercise plans, although her HbA1c remains above the target of 7.0%. They agree to adjust her regimen to Glucovance 2.5 mg/500 mg twice daily, and she is advised to check her morning blood glucose at least twice in the first week to monitor for nocturnal hypoglycemia.
CLICK HERE FOR TREATMENT
Rationale and Comments: While Patient K’s fasting levels are close to target, her postprandial readings are still elevated. Metformin will continue to address her fasting and midday glucose levels, while glyburide will help stimulate insulin production. Patient K will need education on recognizing signs of hypoglycemia and understanding when to contact her physician.
